TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31199592

Group type: EXPERIMENTAL
Intervention: Moderate caloric restriction (250 kcal)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High caloric restriction (600 kcal)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Caloric restriction with aerobic exercise
Number of subjects: 88

Group type: COMPARATOR
Intervention: Aerobic exercise alone
Number of subjects: 88
Study: 27798731

Group type: EXPERIMENTAL
Intervention: Aggressive strategy targeting LDL-C of 70 mg/dL and BP of 120/70 mmHg
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard strategy targeting LDL-C of 100 mg/dL and BP of 140/90 mmHg
Number of subjects: 97
Study: 25873267

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 312

Group type: COMPARATOR
Intervention: Vitamin D analog
Number of subjects: 312
Study: 23813302

Group type: EXPERIMENTAL
Intervention: TRV027
Number of subjects: 0
Study: 20696677

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (DP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Docetaxel plus carboplatin (DC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC)
Number of subjects: 90
Study: 19233764

Group type: EXPERIMENTAL
Intervention: Minimally invasive direct coronary artery bypass (MIDCAB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 54
Study: 17965863

Group type: EXPERIMENTAL
Intervention: Azygos vein preserved (Group A)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Azygos vein ligated (Group B)
Number of subjects: 96
Study: 15367055

Group type: EXPERIMENTAL
Intervention: Sertraline (75 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11339590

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-penetrating deep sclerectomy (NPDS) without collagen implants
Number of subjects: 17
Study: 9848530

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) therapy with bioabsorbable polyglactin 910 barriers
Number of subjects: 26
Study: 10085713

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia (CC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (BC)
Number of subjects: 122
Study: 1863945

Group type: EXPERIMENTAL
Intervention: 40 mg of famotidine nightly for four to eight weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: 300 mg of ranitidine nightly for four to eight weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 20 mg of famotidine nightly during six-month maintenance treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: 150 mg of ranitidine nightly during six-month maintenance treatment
Number of subjects: 160
Study: 6849826

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg twice weekly for 1 year)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Phlebotomy (twice-monthly phlebotomies of 400 ml whole blood for 1 year)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Phlebotomy
Number of subjects: 61
Study: 31525168

Group type: EXPERIMENTAL
Intervention: Protein Supplementation (PRO; 28.7 g casein protein)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Carbohydrate Placebo (PLA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Protein Supplementation (PRO)
Number of subjects: 60
Study: 30326527

Group type: EXPERIMENTAL
Intervention: HIGH (150% of habitual PA)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LOW (50% of habitual PA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HABITUAL (100% of habitual PA)
Number of subjects: 15
Study: 26754626

Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan)
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Known diabetes mellitus (HbA1c ≥ 6.5%)
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Undiagnosed diabetes mellitus (HbA1c > 6.5%)
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Pre-diabetes mellitus (HbA1c 6.0%-6.4%)
Number of subjects: 8399

Group type: COMPARATOR
Intervention: No diabetes mellitus (HbA1c < 6.0%)
Number of subjects: 8399
Study: 24555542

Group type: EXPERIMENTAL
Intervention: Motivation to shop for healthful foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivation to shop for products based on taste
Number of subjects: 0
Study: 22463472

Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS) education
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard hypoglycemia education (Control)
Number of subjects: 36
Study: 20198424

Group type: COMPARATOR
Intervention: 15 mg lansoprazole daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole and 300 mg rebamipide daily
Number of subjects: 41
Study: 18291396

Group type: EXPERIMENTAL
Intervention: Propofol (n = 14) combined with fentanyl 1 microg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dexmedetomidine (n = 12) 1 microg/kg for 10 minutes, followed by 0.2 to 0.5 microg/kg/min
Number of subjects: 26
Study: 15746835

Group type: EXPERIMENTAL
Intervention: High-almond diet (20% of total energy from almonds)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-almond diet (10% of total energy from almonds)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control diet (0% of total energy from almonds)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Almond intake (overall)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Almond intake (dose-response effect)
Number of subjects: 16
Study: 14518160

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (up to 400 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10380063

Group type: EXPERIMENTAL
Intervention: 13-day titration group to 150 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16-day titration group to 200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10-day titration group
Number of subjects: 0
Study: 9408278

Group type: EXPERIMENTAL
Intervention: Surgery (primary treatment for cutaneous malignant melanoma)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Selective lymphadenectomy with identification of the sentinel node
Number of subjects: 132

Group type: COMPARATOR
Intervention: Elective lymph node dissection
Number of subjects: 132
Study: 8228191

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (enalapril or lisinopril 20 mg once a day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Calcium antagonists (nifedipine 20 mg twice a day or lacidipine 4 mg once a day)
Number of subjects: 75
Study: 2937811

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg/d
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Aspirin 3,900 mg/d
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Etodolac 100 mg/d
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Etodolac 50 mg/d
Number of subjects: 264
Study: 30641852

Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fusion surgery
Number of subjects: 0
Study: 28854851

Group type: EXPERIMENTAL
Intervention: Group counseling using A-B-C technique
Number of subjects: 40
Study: 27503012

Group type: EXPERIMENTAL
Intervention: Telmisartan combined with leflunomide (20 mg/d)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Telmisartan combined with clopidogrel (50 mg/d)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 400
Study: 24549212

Group type: EXPERIMENTAL
Intervention: IUI 1 day after LH rise
Number of subjects: 412

Group type: COMPARATOR
Intervention: IUI 2 days after LH rise
Number of subjects: 412
Study: 22549300

Group type: EXPERIMENTAL
Intervention: Heart failure patients with impaired left ventricular function
Number of subjects: 7865

Group type: EXPERIMENTAL
Intervention: Heart failure patients with three or more comorbidities
Number of subjects: 7865

Group type: EXPERIMENTAL
Intervention: Overall cohort of heart failure patients
Number of subjects: 7865

Group type: EXPERIMENTAL
Intervention: Low-risk women under 50 years old
Number of subjects: 7865

Group type: EXPERIMENTAL
Intervention: High-risk octogenarian males
Number of subjects: 7865
Study: 19347878

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17460947

Group type: EXPERIMENTAL
Intervention: BB536 yogurt (2 x 100 g per day for 14 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo yogurt (2 x 100 g per day for 14 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BB536 yogurt
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 40
Study: 16246662

Group type: EXPERIMENTAL
Intervention: Laminaria
Number of subjects: 58

Group type: COMPARATOR
Intervention: No Laminaria
Number of subjects: 58
Study: 12475469

Group type: EXPERIMENTAL
Intervention: Handgrip (HG) for 2 min during impending syncope
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 19
Study: 7966027

Group type: EXPERIMENTAL
Intervention: FSH (450 iu) injected i.m. on day 2 of the cycle
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FSH (225 iu) injected on the day the dominant follicle was 14-15 mm in diameter
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (2 ml 0.9% normal saline)
Number of subjects: 12
Study: 3331977

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally) in normal children (NC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally) in short children (SC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg orally) in normal adults (NA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pyridostigmine (60 mg orally) in short children (SC) vs Insulin hypoglycaemia (IH)
Number of subjects: 43
Study: 29028448

Group type: EXPERIMENTAL
Intervention: 6-month behavioral intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal-weight (NW) controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 30
Study: 28096254

Group type: EXPERIMENTAL
Intervention: Antibiotic prescription (phenoxymethylpenicillin used in 67% of cases)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Referral to hospital
Number of subjects: 401
Study: 25762226

Group type: EXPERIMENTAL
Intervention: Maintenance programme consisting of 2 hours (1 hour individually tailored exercise training and 1 hour education programme) every 3 months for 1 year
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 110
Study: 22806487

Group type: EXPERIMENTAL
Intervention: Vaizey score
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Wexner score
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fecal Incontinence Quality of Life Scale (FIQL)
Number of subjects: 80
Study: 21712486

Group type: EXPERIMENTAL
Intervention: LCS101 (2 g capsules thrice daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 18027055

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Toupet fundoplication
Number of subjects: 200
Study: 16802490

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.25 microg/kg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Fentanyl 1 microg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Remifentanil and Fentanyl
Number of subjects: 63
Study: 15609595

Group type: EXPERIMENTAL
Intervention: Guben Xiaoliu Capsule (GXC) plus chemotherapy (CT) in Group A
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Guben Xiaoliu Capsule (GXC) alone in Group B
Number of subjects: 198

Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone in Group C
Number of subjects: 198
Study: 10972447

Group type: EXPERIMENTAL
Intervention: Smoking abstinence (n = 16)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continued smoking (n = 5)
Number of subjects: 21
Study: 9049577

Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8315146

Group type: EXPERIMENTAL
Intervention: Medium level of structure (categorized words presented in randomized order)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Signal detection analysis (d')
Number of subjects: 0

Group type: COMPARATOR
Intervention: High and low structured material
Number of subjects: 0
Study: 2884197

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms/hr i.v. for 48 hrs)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Vasopressin (0.1 U/min i.v. for 48 hrs)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms/hr i.v. for 7 days after initial treatment)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (after initial treatment)
Number of subjects: 49
Study: 31136042

Group type: EXPERIMENTAL
Intervention: Standard therapy (5000 IU daily for 80 days)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Stoss therapy (100,000 IU weekly for 4 weeks)
Number of subjects: 151
Study: 30248301

Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Interval Training (HIIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined Training (PRT + HIIT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 36
Study: 27882535

Group type: EXPERIMENTAL
Intervention: KingVision™
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Airtraq™
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: A.P. Advance™ MAC
Number of subjects: 480

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 480
Study: 25887978

Group type: EXPERIMENTAL
Intervention: Use of a magnifying loupe (x2.5)
Number of subjects: 182

Group type: COMPARATOR
Intervention: No use of a magnifying loupe
Number of subjects: 182
Study: 23138409

Group type: EXPERIMENTAL
Intervention: Dynamic flamingo exercise (one-leg standing with eyes open for a total of 1 min, three times a day for 6 months)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Dynamic flamingo exercise
Number of subjects: 865

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 865
Study: 21478808

Group type: EXPERIMENTAL
Intervention: Single-session panretinal photocoagulation (SS-PRP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multiple-session panretinal photocoagulation (MS-PRP)
Number of subjects: 40
Study: 19263185

Group type: EXPERIMENTAL
Intervention: Adapted cow's milk-based formula
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Banked human milk
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed in the hospital
Number of subjects: 6209

Group type: COMPARATOR
Intervention: Cow's milk-based formula exposure
Number of subjects: 6209

Group type: EXPERIMENTAL
Intervention: Early regular daily feeding with cow's milk-based formula
Number of subjects: 6209
Study: 17913505

Group type: EXPERIMENTAL
Intervention: Hookwire technique (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radio-guided surgery (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Finger palpation (control for both groups)
Number of subjects: 50
Study: 15750987

Group type: EXPERIMENTAL
Intervention: on-line HFR
Number of subjects: 6

Group type: COMPARATOR
Intervention: pre-cartridge
Number of subjects: 6
Study: 11581005

Group type: EXPERIMENTAL
Intervention: Micronized DHEA, 25 mg/day for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9152127

Group type: EXPERIMENTAL
Intervention: White infants
Number of subjects: 4099

Group type: EXPERIMENTAL
Intervention: Black infants
Number of subjects: 4099

Group type: COMPARATOR
Intervention: Race as a factor
Number of subjects: 4099
Study: 8267129

Group type: EXPERIMENTAL
Intervention: Clozapine (410.5 mg/day, SD = 45.8)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Haloperidol (24.8 mg/day, SD = 5.5)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 39
Study: 2447995

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31385847

Group type: EXPERIMENTAL
Intervention: Participants who were male, white, low-income, college graduates, and younger
Number of subjects: 2605

Group type: EXPERIMENTAL
Intervention: Information given about initiation of opioid use (received prescription opioids from a doctor)
Number of subjects: 2605

Group type: EXPERIMENTAL
Intervention: Information given about initiation of opioid use (took prescription opioids from a friend)
Number of subjects: 2605
Study: 29958916

Group type: EXPERIMENTAL
Intervention: sfCOMP-Bio
Number of subjects: 121

Group type: COMPARATOR
Intervention: sCOMP-Bio
Number of subjects: 121

Group type: COMPARATOR
Intervention: sCOMP-Ana
Number of subjects: 121
Study: 27028445

Group type: EXPERIMENTAL
Intervention: Warfarin plus low-dose aspirin (75 mg)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 316
Study: 25698450

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control (younger patients)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control (elderly patients)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Age as a prognostic factor
Number of subjects: 127
Study: 24223736

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOLs
Number of subjects: 861

Group type: COMPARATOR
Intervention: Hydrophilic acrylic IOLs
Number of subjects: 861
Study: 21138720

Group type: EXPERIMENTAL
Intervention: Naltrexone (Revia)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 19756236

Group type: EXPERIMENTAL
Intervention: Ultrabrief right unilateral ECT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ultrabrief bilateral ECT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard pulse width bilateral ECT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard pulse width unilateral ECT
Number of subjects: 90
Study: 16899965

Group type: EXPERIMENTAL
Intervention: Intermittent alternating right-left stimulation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intermittent simultaneous bilateral stimulation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous bilateral stimulation
Number of subjects: 21
Study: 12814449

Group type: EXPERIMENTAL
Intervention: Netilmicin (100 mg) administered as a maximum of four successive intravenous infusions of 30 min, at 8-h intervals.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Population covariate model based on sex and creatinine clearance.
Number of subjects: 62
Study: 11082221

Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy with FAM (5‐fluorouracil, Adriamycin, and mitomycin C)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (28 patients who had only undergone radical resection)
Number of subjects: 53
Study: 8867250

Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 1644095

Group type: EXPERIMENTAL
Intervention: Aggressive lipid-altering therapy
Number of subjects: 0
Study: 6376265

Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30916898

Group type: EXPERIMENTAL
Intervention: Copolymer-1 (Cop-1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30382923

Group type: EXPERIMENTAL
Intervention: Electrically guided implantation of the LV lead using electrical mapping towards the latest LV activation.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Imaging-guided implantation of the LV lead using echocardiography and myocardial perfusion imaging.
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 122
Study: 25345540

Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paraffin oil (placebo)
Number of subjects: 80
Study: 24338799

Group type: EXPERIMENTAL
Intervention: Dyadic exercise regimen (individually tailored walking regimen designed to become progressively intensive, lasting between 20-30 minutes, at least five times per week)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no exercise regimen)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Dyadic exercise regimen
Number of subjects: 131
Study: 23270333

Group type: EXPERIMENTAL
Intervention: LI10903F (300 mg thrice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (300 mg thrice daily)
Number of subjects: 50
Study: 20702111

Group type: EXPERIMENTAL
Intervention: Knee joint cryotherapy application (20 min with a crushed-ice bag)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (rest for 20 min)
Number of subjects: 20
Study: 18399341

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia (10 mg of 0.5% hyperbaric bupivacaine)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional spinal anaesthesia (10 mg of 0.5% hyperbaric bupivacaine)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional spinal anaesthesia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia
Number of subjects: 74
Study: 15276098

Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 1387
Study: 11557651

Group type: EXPERIMENTAL
Intervention: Vitamin E 500 IU/day
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 9566367

Group type: EXPERIMENTAL
Intervention: tPA treatment
Number of subjects: 1000
Study: 7995835

Group type: EXPERIMENTAL
Intervention: Endothelial cell seeded graft limb
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-seeded graft limb (Control)
Number of subjects: 15